Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
Clinical Drug Investigation · 2026-11 · 46 (11) · 1299-1312
DOI: 10.1007/s40261-026-01592-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 19.09.2026. Verfasst von Mahek Garg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merck Sharp & Dohme LLC, A subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Health Care Costs. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc..
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Indolent non-Hodgkin's lymphomas (NHL) are associated with relapses necessitating recurrent treatment and lifelong care. However, contemporary real-world evidence of the disease burden among patients with indolent NHLs remains limited. This study describes treatment patterns, healthcare resource use (HRU), and costs among patients with follicular lymphoma (FL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL) in the USA. METHODS: Adults with newly diagnosed FL, WM, and MZL were identified in claims data (October 2015-June 2021). The study period spanned from the index date (first observed diagnosis code) until end of continuous enrollment or data availability. Treatment patterns were described during the study period by lines of therapy (LOTs). HRU and costs per-patient-per-month (PPPM) were described overall and by LOTs. RESULTS: This study included 2805 patients with FL, 791 with WM, and 2207 with MZL with a median follow-up of > 20 months each. Bendamustine-based therapies and rituximab monotherapy were most common. In later lines, bendamustine-based therapies declined while rituximab monotherapy and ibrutinib-based therapies increased. Mean all-cause total costs were US $12,402, US $8445, and US $9580 PPPM for patients with FL, WM, and MZL, respectively. Disease-related medical costs constituted > 50% of all-cause total costs, with most hospitalization costs being disease-related. In FL, HRU and costs tended to increase by LOT, driven by FL-related hospitalizations. Trends in HRU and costs across LOTs were less clear for WM and MZL. CONCLUSIONS: Our study suggests that indolent NHLs are associated with a significant economic burden that tends to increase across LOTs in FL, highlighting the need for better therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck Sharp & Dohme LLC, A subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
- Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Yan.Song@analysisgroup.com.
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc.
Zitieren
APA
Garg, M., Satija, A., Song, Y., Meade, B., Signorovitch, J., & Gandra, S. (2026). Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA. Clinical Drug Investigation, 46(11), 1299-1312. https://doi.org/10.1007/s40261-026-01592-6
Vancouver
Garg M, Satija A, Song Y, Meade B, Signorovitch J, Gandra S. Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA. Clinical Drug Investigation. 2026;46(11):1299-1312. doi:10.1007/s40261-026-01592-6
BibTeX
@article{Garg2026,
author = {Garg, Mahek and Satija, Ambika and Song, Yan and Meade, Benjamin and Signorovitch, James and Gandra, Shravanthi},
title = {Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {11},
pages = {1299--1312},
doi = {10.1007/s40261-026-01592-6}
}
EUVIMED